Patents by Inventor Jorgen Frokiaer

Jorgen Frokiaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutically active ?-MSH analogues
    Patent number: 8703702
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 22, 2014
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Method for preventing or reducing acute renal failure by administration of therapeutically active ?-MSH analogues
    Patent number: 8563508
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: October 22, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Therapeutically Active Alpha-MSH Analogues
    Publication number: 20130252891
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2013
    Publication date: September 26, 2013
    Applicant: AbbVie Inc.
    Inventors: Thomas E.N. JONASSEN, Soren NIELSEN, Jorgen FROKIAER, Bjarne Due LARSEN
  • Therapeutically active alpha MSH analogues
    Patent number: 8466104
    Abstract: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 18, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • THERAPEUTICALLY ACTIVE ALPHA MSH ANALOGUES
    Publication number: 20090069242
    Abstract: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 12, 2009
    Applicant: ACTION PHARMA A/S
    Inventors: Thomas E.N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Use of alpha-MSH and EPO for preventing or treating ischemic conditions
    Publication number: 20060063705
    Abstract: Alpha-melanocyte stimulating hormone (?-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.
    Type: Application
    Filed: November 1, 2005
    Publication date: March 23, 2006
    Inventors: Soren Nielsen, Jorgen Frokiaer, Thomas Jonassen, Thorbjorn Bjerke
  • Methods for treatment of diseases associated with inflammation under non-ischemic conditions
    Publication number: 20020061849
    Abstract: A disease associated with inflammation under non-ischemic conditions is treated or prevented by administering (1) &agr;-melanocyte simulating hormone (&agr;-MSH) and/or a &agr;-MSH equivalent, and/or (2) erythropoietin (EPO) and/or an EPO equivalent, to the individual in need thereof.
    Type: Application
    Filed: May 2, 2001
    Publication date: May 23, 2002
    Inventors: Soren Nielsen, Jorgen Frokiaer, Thomas Engelbrecht Norkild Jonassen, Thorbjorn Bjerke
  • Use of alpha-MSH and EPO for preventing or treating ischemic conditions
    Publication number: 20020037832
    Abstract: Alpha—melanocyte stimulating hormone (&agr;-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.
    Type: Application
    Filed: May 2, 2001
    Publication date: March 28, 2002
    Inventors: Soren Nielsen, Jorgen Frokiaer, Thomas Engelbrecht Norkild Jonassen, Thorbjorn Bjerke